Thermo Fisher Scientific agreed to acquire Clario in a cash deal that pays roughly $8.9 billion upfront plus contingent consideration, valuing the clinical-trial data and software specialist at up to about $9.4 billion. Thermo Fisher said the purchase secures a data solutions platform used by sponsors and CROs to manage trial operations and patient data. The deal combines Thermo Fisher’s laboratory and life‑science product footprint with Clario’s trial software and data services, signaling a consolidation of lab logistics and trial‑data infrastructure. For sponsors, the integration could streamline data flows from instruments to trial‑management systems; for competitors, it raises the bar on scale and vertical integration in trial tech. Thermo Fisher framed the acquisition as a strategic step to expand its digital and services capabilities across clinical development. The transaction will be watched for integration execution risks and any regulatory scrutiny given its size and implications for the clinical‑trial software market.